Most Read Articles
Stephen Padilla, 25 Jul 2019
Nonvitamin K antagonist oral anticoagulants (NOACs) appear to confer more clinical benefits to elderly patients with atrial fibrillation (AF) than vitamin K antagonist anticoagulants (VKAs), suggests a study, adding that this is primarily driven by the lower rates of major bleeding.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

12 Dec 2016

Associate Professor Ng Lee Ching, Director of the Environmental Health Institute (EHI) at the National Environment Agency (NEA), Singapore, speaks about the role of primary care physicians and government agencies in preventing dengue epidemics.

22 Aug 2018
In patients with atrial fibrillation (AF) naïve to oral anticoagulants (OACs), standard-dose nonvitamin K antagonist OACs (NOACs) provides better survival benefits than warfarin, a recent meta-analysis has shown.

Entecavir slightly better than lamivudine for patients with HBV-related AE, ACLF

08 Jul 2017

Entecavir and lamivudine demonstrate comparable effects on the mortality rate of patients with chronic hepatitis B virus (HBV)-related acute exacerbation with or without acute-on-chronic liver failure (ACLF), reports a study. In patients with ACLF, however, entecavir delivers a more favourable long-term outcome and is associated with greater clinical improvements.

Researchers performed a comprehensive literature search of studies on therapy involving entecavir or lamivudine for chronic HBV-related acute exacerbation with or without ACLF published before December 2015.

Short- (within 4 months) and long-term (beyond 4 months) mortality were the main outcomes. The secondary outcomes were virological and biochemical responses, ACLF recurrence, and safety.

Three prospective and eight retrospective cohort studies met the inclusion criteria, involving a total of 1,491 patients. Overall, short- (risk ratio [RR], 0.99; 95 percent CI, 0.78 to 1.27) and long-term mortality rates (RR, 0.82; 0.45 to 1.52) were similar among all patients who received entecavir or lamivudine.

On the other hand, long-term outcome was more favourable in patients with ACLF who received entecavir vs lamivudine (RR, 0.60; 0.45 to 0.80). In addition, entecavir yielded more efficient virological and biochemical responses than did lamivudine with respect to the HBV DNA undetectable rate (RR, 1.34; 1.09 to 1.63), HBV DNA reduction rate (weighted mean difference, ‒0.41; ‒0.69 to ‒0.13) and serum alanine aminotransferase normalization rate (RR, 1.13; 1.05 to 1.21).

Additional larger, long-term randomized controlled trials are warranted to confirm these findings, according to researchers.

Oral nucleos(t)ide analogues are commonly given in patients with chronic HBV-related acute exacerbation and ACLF, researchers said. This study provided evidence to the safety and efficacy of entecavir and lamivudine to such patients.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 25 Jul 2019
Nonvitamin K antagonist oral anticoagulants (NOACs) appear to confer more clinical benefits to elderly patients with atrial fibrillation (AF) than vitamin K antagonist anticoagulants (VKAs), suggests a study, adding that this is primarily driven by the lower rates of major bleeding.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

12 Dec 2016

Associate Professor Ng Lee Ching, Director of the Environmental Health Institute (EHI) at the National Environment Agency (NEA), Singapore, speaks about the role of primary care physicians and government agencies in preventing dengue epidemics.

22 Aug 2018
In patients with atrial fibrillation (AF) naïve to oral anticoagulants (OACs), standard-dose nonvitamin K antagonist OACs (NOACs) provides better survival benefits than warfarin, a recent meta-analysis has shown.